Insulin resistance reduction

“Insulin resistance reduction” refers broadly to strategies—pharmacologic or lifestyle—that improve cellular responsiveness to endogenous or exogenous insulin. This effect can be achieved through direct action on components of the canonical signaling pathway downstream from the insulin receptor—including IRS proteins, PI3K/Akt pathway members—or via indirect effects such as weight loss or anti-inflammatory actions. While many drugs aim for this outcome due to its central role in type 2 diabetes pathogenesis and cardiovascular risk mitigation,[4] there is no single molecular entity called “Insulin resistance reduction.” Instead, it represents an important clinical endpoint targeted through diverse mechanisms involving multiple molecular targets.

Other names

Insulin sensitizationImproved insulin sensitivityDecreased insulin resistance

Mechanisms depend on the drug class:\n - Metformin reduces hepatic glucose production and increases peripheral glucose uptake by enhancing muscle sensitivity to insulin.\n - Thiazolidinediones activate PPARγ, altering gene expression in adipose tissue and increasing cellular responsiveness to insulin.\n Additional mechanisms involve inhibition of negative regulators of the insulin pathway such as PTP1B[1].